Balchem Corp. 10-Q Summary: Period Ended June 30, 2002
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Balchem Corporation, filed for the period ended June 30, 2002. The company develops, manufactures, and markets specialty performance ingredients for the food, feed, and medical sterilization industries. Operations are divided into three segments: Specialty Products, Encapsulated/Nutritional Products, and Unencapsulated Feed Supplements (the latter resulting from a 2001 acquisition).
Key Financial Metrics (Six Months Ended June 30, 2002)
- Net Sales: $30,057,000 (up 65.0% from $18,213,000 in the prior year).
- Gross Profit: $11,858,000 (Gross Margin: 39.5%, down from 42.3% in the prior year).
- Net Earnings: $3,643,000 (up 61.1% from $2,261,000 in the prior year).
- Earnings Per Share (Diluted): $0.74 (up from $0.47 in the prior year).
- Operating Cash Flow: $4,798,000 (up significantly from $596,000 in the prior year).
- Capital Expenditures: $4,306,000 (projected total for 2002 is $8,000,000).
- Debt: Total debt consists of a $13,500,000 term loan (current portion $1,745,000; long-term portion $10,452,000). No amounts drawn on the $3,000,000 revolving facility.
- Liquidity: Cash and cash equivalents totaled $2,848,000. Working capital increased to $11,035,000.
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by the Encapsulated/Nutritional Products segment, which saw sales increase 107.0% to $14,113,000. This growth is attributed to the 2001 acquisition of DCV, Inc. assets and organic growth in domestic food and animal nutrition markets. The Specialty Products segment grew modestly by 2.0%.
- Margin Compression: Gross margin percentage declined from 42.3% to 39.5%. Management attributes this to increased sales of lower-margin feed products in the Unencapsulated Feed Supplements segment, which incurred an operating loss of $209,000 for the period.
- Operating Expenses: Increased 29.7% to $5,768,000 due to higher advertising, personnel costs for sales/marketing, and R&D spending ($1,009,000). However, operating expenses as a percentage of sales decreased from 24.4% to 19.2%.
- Interest Expense: Increased to $205,000 from $76,000 due to the term loan financing the 2001 acquisition.
Guidance, Outlook, and Risks
- Capital Projects: The company is expanding manufacturing and distribution facilities in Verona, Missouri, and has leased 20,000 square feet of office space to serve as general offices and a laboratory.
- Stock Repurchase: The board authorized an extension of the stock repurchase program for up to an additional 600,000 shares through June 30, 2003.
- Contingent Consideration: The 2001 acquisition agreement allows for up to an additional $2,750,000 in payments based on gross margin thresholds over three years. No such consideration has been earned or paid as of June 30, 2002.
- Accounting Changes: The company adopted SFAS No. 142 (Goodwill) and SFAS No. 144 (Impairment) in 2002. Goodwill is no longer amortized but tested for impairment annually. No impairment was indicated.
- Market Risk: The company has exposure to interest rate risk on its variable-rate term loan (LIBOR + 1.25%). A 100 basis point increase would increase annual interest expense by approximately $122,000. There is no material exposure to foreign currency or commodity price risk.
Investor Verification Checklist
- Verify the sustainability of the 107% sales growth in the Encapsulated/Nutritional segment post-acquisition.
- Monitor the Unencapsulated Feed Supplements segment, which is currently operating at a loss and dragging down overall gross margins.
- Review the company's ability to meet the $8,000,000 capital expenditure projection for 2002 given current cash flow.
- Assess the potential liability for the $2,750,000 contingent consideration on the 2001 acquisition based on future gross margin performance.
- Confirm compliance with debt covenants, specifically financial ratios required by the Loan Agreement.